Skip to content

Comparative study of the effect and tolerance of sulfalene/pyrimethamine/amodiaquine versus artemether/lumefantrine for treatment of malaria

Comparative study of the efficiency and tolerance of the sulfalene/pyrimethamine/amodiaquine versus artemether/lumefantrine for the treatment of simple Plasmodium falciparum malaria

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201508001193368
Enrollment
Unknown
Registered
2015-07-08
Start date
2005-11-01
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria

Interventions

amodiaquine plus sulpahalene-pyrimethamine

Sponsors

Pfizer Global pharmaceuticals
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: boby weight >/= 5 kg History of fever microscopically confirmed pure Plasmodium falciparum infection >/= 2000/uL Presence or history of fever (temp. >37.4) written informed consent

Exclusion criteria

Exclusion criteria: severe malaria History of alergy to study drugs Presence of concomitant illness Signs of severe malnutrition Patient with history of hepatic, cardiac or renal disease.

Design outcomes

Primary

MeasureTime frame
Clinical and parasitological cure

Secondary

MeasureTime frame
Parasites and fever clearance times;Gametocytaemia;adverse drug events

Countries

Nigeria

Contacts

Public ContactAkintunde Sowunmi

Professor

akinsowunmi@hotmail.com08052157893

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026